Can-FiteBioPharma Ltd. (NYSE: CANF) is an Israeli biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities. The company has an advanced pipeline of proprietary compounds in phase II and III clinical development stage, which address autoimmune-inflammatory and cancer diseases. The company’s platform technology utilizes the Gi protein associated A3 adenosine receptor (A3AR) as a therapeutic target. A3AR is highly expressed in inflammatory and cancer cells where low expression is found in normal cells, suggesting that the receptor could be a unique target for pharmacological intervention. For more information, visit the company’s website at www.canfite.co.il.